Apparent Declining Efficacy in Randomized Trials: Examples of the Thai RV144 HIV Vaccine and South African CAPRISA 004 Microbicide Trials

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2011 Nov 3

PMID 22045345

Citations 22

Authors

Justin J OHagan

Miguel A Hernan

Rochelle P Walensky

Marc Lipsitch

Affiliations

Soon will be listed here.

Citing Articles

Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.

Juraska M, Bai H, deCamp A, Magaret C, Li L, Gillespie K Proc Natl Acad Sci U S A. 2024; 121(4):e2308942121.

PMID: 38241441 PMC: 10823214. DOI: 10.1073/pnas.2308942121.

Competing Heterogeneities in Vaccine Effectiveness Estimation.

Nikas A, Ahmed H, Zarnitsyna V Vaccines (Basel). 2023; 11(8).

PMID: 37631880 PMC: 10458793. DOI: 10.3390/vaccines11081312.

Competing Heterogeneities in Vaccine Effectiveness Estimation.

Nikas A, Ahmed H, Zarnitsyna V ArXiv. 2023; .

PMID: 37205263 PMC: 10187365.

Estimating Waning of Vaccine Effectiveness: A Simulation Study.

Nikas A, Ahmed H, Zarnitsyna V Clin Infect Dis. 2022; 76(3):479-486.

PMID: 36056892 PMC: 10169445. DOI: 10.1093/cid/ciac725.

Joint modeling of time-varying HIV exposure and infection for estimation of per-act efficacy in HIV prevention trials.

Brown E, Dominguez Islas C, Zhang J Stat Commun Infect Dis. 2021; 12(Suppl 1).

PMID: 34141053 PMC: 8204698. DOI: 10.1515/scid-2019-0016.

References

Vaupel J, Yashin A . Heterogeneity's ruses: some surprising effects of selection on population dynamics. Am Stat. 1985; 39(3):176-85. View

Bassler D, Briel M, Montori V, Lane M, Glasziou P, Zhou Q . Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010; 303(12):1180-7. DOI: 10.1001/jama.2010.310. View

Arrighi H, Hertz-Picciotto I . The evolving concept of the healthy worker survivor effect. Epidemiology. 1994; 5(2):189-96. DOI: 10.1097/00001648-199403000-00009. View

Bassler D, Ferreira-Gonzalez I, Briel M, Cook D, Devereaux P, Heels-Ansdell D . Systematic reviewers neglect bias that results from trials stopped early for benefit. J Clin Epidemiol. 2007; 60(9):869-73. DOI: 10.1016/j.jclinepi.2006.12.006. View

Celum C, Wald A, Lingappa J, Magaret A, Wang R, Mugo N . Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010; 362(5):427-39. PMC: 2838503. DOI: 10.1056/NEJMoa0904849. View

Vaupel J, Manton K, Stallard E . The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography. 1979; 16(3):439-54. View

Moride Y, Abenhaim L, Yola M, Lucein A . Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994; 47(7):731-7. DOI: 10.1016/0895-4356(94)90170-8. View

Montori V, Devereaux P, Adhikari N, Burns K, Eggert C, Briel M . Randomized trials stopped early for benefit: a systematic review. JAMA. 2005; 294(17):2203-9. DOI: 10.1001/jama.294.17.2203. View

Weller S, Davis K . Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002; (1):CD003255. DOI: 10.1002/14651858.CD003255. View

10.

Yashin A, Iachine I . How frailty models can be used for evaluating longevity limits: taking advantage of an interdisciplinary approach. Demography. 1997; 34(1):31-48. View

11.

Ford I, Norrie J, Ahmadi S . Model inconsistency, illustrated by the Cox proportional hazards model. Stat Med. 1995; 14(8):735-46. DOI: 10.1002/sim.4780140804. View

12.

Yang Y, Gilbert P, Longini I, Halloran M . A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact. Ann Appl Stat. 2009; 2(4):1409-1431. PMC: 2630256. DOI: 10.1214/08-AOAS193. View

13.

Niccolai L, Rowhani-Rahbar A, Jenkins H, Green S, Dunne D . Condom effectiveness for prevention of Chlamydia trachomatis infection. Sex Transm Infect. 2005; 81(4):323-5. PMC: 1745001. DOI: 10.1136/sti.2004.012799. View

14.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

15.

Hernan M . The hazards of hazard ratios. Epidemiology. 2009; 21(1):13-5. PMC: 3653612. DOI: 10.1097/EDE.0b013e3181c1ea43. View

16.

Padian N, McCoy S, Balkus J, Wasserheit J . Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010; 24(5):621-35. PMC: 3695696. DOI: 10.1097/QAD.0b013e328337798a. View

17.

H Gray R . Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings). Curr Opin HIV AIDS. 2009; 4(4):274-8. PMC: 2883269. DOI: 10.1097/COH.0b013e32832c2553. View

18.

Pocock S, White I . Trials stopped early: too good to be true?. Lancet. 1999; 353(9157):943-4. DOI: 10.1016/S0140-6736(98)00379-1. View

19.

Warner L, Newman D, Austin H, Kamb M, Douglas Jr J, Malotte C . Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status. Am J Epidemiol. 2004; 159(3):242-51. DOI: 10.1093/aje/kwh044. View

20.

Haber M, Ndikuyeze A . Estimation of individual and population vaccination effectiveness from time-to-event data. Stat Med. 1998; 17(22):2617-23. DOI: 10.1002/(sici)1097-0258(19981130)17:22<2617::aid-sim951>3.0.co;2-h. View